PRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric adenocarcinoma

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515221-29-00

Acronym

PRODIGE 51 - GASTFOX

Enrollment

507

Registered

2024-07-04

Start date

2016-12-19

Completion date

2025-02-27

Last updated

2024-07-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally advanced or metastatic oesogastric adenocarcinoma

Brief summary

To assess the progression free survival at 12 months after the last randomisation

Detailed description

To assess the overall survival

Interventions

DRUGANHYDROUS DOCETAXEL

DRUGFLUOROURACIL

DRUGOXALIPLATIN

DRUGCALCIUM LEVOFOLINATE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To assess the progression free survival at 12 months after the last randomisation	—

Secondary

Measure	Time frame
To assess the overall survival	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026